Across TCGA pan-cancer cohorts, GLRX5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GLRX5 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GLRX5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GLRX5 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where GLRX5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.157	0.569	.017	12	view →
HNSC	DFS	Tertile	All	0.524	0.755	.018	11	view →
CCRCC	DFS	Tertile	II,III,IV	0.826	1.000	.009	8	view →
LUAD	DFS	Tertile	II,III,IV	0.930	0.728	.036	2	view →
LSCC	DFS	Tertile	All	0.660	1.000	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: GLRX5 tumor-vs-normal RNA expression · all GLRX5 data types